AdipoGenix Announces the Addition of Three New Members to its Scientific Advisory Board
BOSTON, August 3 2005 – AdipoGenix Inc., a biopharmaceutical company developing small molecule therapies for obesity, type 2 diabetes and associated morbidities, today announced the addition of Richard Bergman, Ph.D., George Bray, M.D. and Manuel Navia, Ph.D. to its scientific advisory board.
“Drs. Bergman and Bray are internationally recognized for their seminal contributions to our understanding of obesity, type 2 diabetes and related metabolic diseases, and Dr. Navia is similarly recognized as a leader in applying structure-based approaches to drug discovery and development,” said Ed Cannon, Ph.D., CEO of AdipoGenix. “These three outstanding scientists add significant clinical and drug development expertise to our Scientific Advisory Board, and will provide important guidance as we advance our lead programs toward the clinic.”
Drs. Bergman, Bray and Navia join AdipoGenix founders and scientific advisors, Drs. Barbara Corkey, Paul Pilch, Stephen Farmer, James Hamilton and James Kirkland all of Boston University School of Medicine, and Dr. Jeff Leighton, who previously held a number of senior management positions at Glaxo Inc., including Vice President of Pharmacology and Worldwide Group Director for Cardiovascular and Metabolic Diseases.
Richard Bergman, Ph.D.
Dr. Bergman is the first Keck Foundation Chair in Medicine and is Professor of Physiology and Biophysics at the Keck School of Medicine at the University of Southern California School of Medicine (Los Angeles, CA). He is widely regarded as the leading proponent of applying engineering principles to complex metabolic diseases, including obesity, diabetes and cardiovascular disease. Dr. Bergman originated the “minimal model”, which is now the most widely used methodology for evaluating future diabetes development among at-risk individuals. His recent honors include the 2004 TOPS Award from the North American Association for Study of Obesity (NAASO), 2004 Novo-Nordisk Endowed Lectureship, McGill University, Lilly Award as Outstanding Researcher in Diabetes, and the 2004 Man of Distinction Lifetime Achievement Award from the American Diabetes Association. Dr. Bergman has published over 275 original research articles and has delivered numerous prestigious lectureships, including the Mosenthal Lectureship, the Schwartz Lectureship, and the Berson Lectureship of the Experimental Biology Society.
George Bray, M.D.
Dr. Bray is the founding Executive Director of the Pennington Biomedical Research Center (Baton Rouge, LA) where he also holds the Boyd Professorship. He is Professor of Medicine at Louisiana State University, Professor of Food Science at LSU A&M, and Professor of Physiology and Toxicology at the LSU School of Veterinary Medicine. He founded the North American Association for the Study of Obesity (NAASO), and was the founding editor of its journal, Obesity Research, as well as the International Journal of Obesity and the official journal of the American College of Endocrinologists, called, Endocrine Practice. Dr. Bray has been President of NAASO, of the American Society for Clinical Nutrition and of the International Association for the Study of Obesity and the American College of Endocrinology. Dr. Bray is the recipient of numerous honors including the Joseph Goldberger Award from the American Medical Association, the McCollum Award from the American Society of Clinical Nutrition and the Osborne-Mendel Award from the American Society of Nutritional Sciences. Dr. Bray has also received the TOPS Award from NAASO, the Weight Watchers Award, the Bristol-Myers Squibb Mead Johnson Award in Nutrition and the Stunkard Lifetime Achievement Award. During the past 40 years, Dr. Bray has authored or coauthored more than 1,500 publications, ranging from peer-reviewed articles to reviews, books, book chapters and abstracts.
Manuel Navia, Ph.D.
Dr. Navia is currently an Executive-in-Residence at Oxford Bioscience Partners. He is an expert in the field of X-ray crystallography, and has focused his career on the application of structural biology to the design and development of novel therapeutic agents through the application of structure-based drug design. In 1980, Dr. Navia established the first industrial macromolecular structure laboratory in the U.S., at Merck & Co., Inc., where he worked on the structures of human neutrophil elastase (a drug target for emphysema) and of carbonic anhydrase (for ocular hypertension and glaucoma). From 1989 to 1997, Dr. Navia was Vice-President and Senior Scientist at Vertex Pharmaceuticals in Cambridge, MA, where his interests in structure-based drug design were focused on studies of the FK506 binding protein and calcineurin (for immunosuppression), IL-1b converting enzyme (for inflammation), and HIV-1 protease (for AIDS), among other projects. Dr. Navia invented the cross-linked enzyme crystal (CLEC) catalyst technology that is currently under development across a broad front by Altus Pharmaceuticals, a company that he co-founded. He was Executive Vice President for Research at Essential Therapeutics, which was formed through the merger of Microcide Pharmaceuticals and the Althexis Company. Prior to the merger, Dr. Navia was Founder, President and Chief Executive Officer of Althexis. Until recently, Dr. Navia was also a member of the Advisory Council of the Office of AIDS Research at the National Institutes of Health, where he chaired the Therapeutic Research Working Group.
About AdipoGenix Inc.
AdipoGenix is a Boston-based biopharmaceutical company developing pharmaceuticals that target human fat tissue to treat obesity and its co-morbidities, including diabetes and cardiovascular disease. Through its proprietary human fat cell-based technology, AdipoGenix identifies nontoxic, small molecule compounds that reduce the fat content in human fat tissue, which is expected to provide therapeutic benefit for these important diseases.
President and CEO
MacDougall BioCommunications, Inc.